Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.

被引：1
|
作者：
Vasseur, Damien
Jovelet, Cecile
Cozic, Nathalie
Mazieres, Julien
Barlesi, Fabrice
Bennouna, Jaafar
Gervais, Radj
Moreau, Lionel
Berard, Henri
Molinier, Olivier
Moro-Sibilot, Denis
Souquet, Pierre Jean
Amour, Elodie
Morin, Franck
Zalcman, Gerard
Soria, Jean-Charles
Westeel, Virginie
Lacroix, Ludovic
Besse, Benjamin
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8526
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.
    Oliva, Stefania
    Bruinink, Davine Hofste op
    RIhova, Lucie
    Spada, Stefano
    van der Holt, Bronno
    Troia, Rossella
    Gambella, Manuela
    Pantani, Lucia
    Grammatico, Sara
    Gilestro, Milena
    Offidani, Massimo
    Ribolla, Rossella
    Galli, Monica
    Hajek, Roman
    Palumbo, Antonio
    Cava, Michele
    Omede, Paola
    van der, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Prospective RT-PCR monitoring of minimal residual disease in acute promyelocytic leukemia (APL) patients enrolled in the multicentric GIMEMA-AIEOP ''AIDA'' trial.
    LoCoco, F
    Diverio, D
    Avvisati, G
    Luciano, A
    DeSantis, S
    Santoro, A
    Pane, F
    Martinelli, G
    Pelicci, PG
    Vegna, ML
    Saglio, G
    Biondi, A
    Mandelli, F
    BLOOD, 1997, 90 (10) : 1734 - 1734
  • [33] IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC
    Kenmotsu, Hirotsugu
    Zhou, Caicun
    Altorki, Nasser
    Felip, Enriqueta
    Vallieres, Eric
    Sugawara, Shunichi
    Sakai, Hiroshi
    Saito, Haruhiro
    Tao, Min
    Kawaguchi, Koji
    Liu, Yunpeng
    Yu, Chong-Jen
    Wu, Qiong
    Lin, Huang
    Wu, Fan
    Bennett, Elizabeth
    Mcnally, Virginia
    Gitlitz, Barbara
    Wakelee, Heather
    ANNALS OF ONCOLOGY, 2022, 33 : S464 - S464
  • [34] Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR
    Dao, T. V.
    Soo, R. A.
    Batra, U.
    Tamayo, M. B. E.
    Tejado Gallegos, L. F.
    Donner, N.
    Alsayed, M.
    Huggenberger, R.
    Reungwetwattana, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S271 - S271
  • [35] Stereotactic Body Radiation Therapy for Central Early-Stage NSCLC: Results of a Prospective Phase I/II Trial
    Roach, Michael C.
    Robinson, Cliff G.
    DeWees, Todd A.
    Ganachaud, Jehan
    Przybysz, Daniel
    Drzymala, Robert
    Rehman, Sana
    Kashani, Rojano
    Bradley, Jeffrey D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1727 - 1732
  • [36] OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC)
    Yong, K.
    De Tute, R.
    De-Silva, D.
    Phillips, E.
    Counsell, N.
    Cavenagh, J.
    Roddie, C.
    Owen, R.
    Streetly, M.
    Schey, S.
    Koh, M.
    Crowe, J.
    Quinn, M.
    D'Sa, S.
    Virchis, A.
    Cook, G.
    Crawley, C.
    Pratt, G.
    Cook, M.
    Ashcroft, J.
    Benjamin, R.
    Adedayo, T.
    Braganca, N.
    Lyons-Lewis, J.
    Smith, P.
    Clifton-Hadley, L.
    Rabin, N.
    Popat, R.
    HAEMATOLOGICA, 2017, 102 : 266 - 266
  • [37] Tumor-informed fixed and patient-specific panels for minimal residual disease (MRD) detection in early-stage NSCLC:a head-to-head comparison
    Zhang, Pengpeng
    Gong, Zetian
    Yu, Yue
    Wang, Xiaoxuan
    Ye, Lei
    Wang, Xiaoqiang
    Tang, Xuan
    Zhang, Chao
    Deng, Wanglong
    Song, Chao
    Xu, Qing
    Li, Yansong
    Wang, Wei
    CANCER RESEARCH, 2023, 83 (07)
  • [38] Prospective evaluation of minimal residual disease (MRD) in high-risk childhood acute lymphoblastic leukemia in the ongoing trial ALL-BFM 2000
    Schrauder, A
    Flohr, T
    Zimmermann, M
    Koch, D
    Stanulla, M
    Lauten, M
    Welte, K
    Bartram, C
    Schrappe, M
    BONE MARROW TRANSPLANTATION, 2002, 30 : S60 - S60
  • [39] The role of adjuvant radiotherapy in carcinoma of the endometrium - Results in 550 patients with pathologic stage I disease
    Irwin, C
    Levin, W
    Fyles, A
    Pintilie, M
    Manchul, L
    Kirkbride, P
    GYNECOLOGIC ONCOLOGY, 1998, 70 (02) : 247 - 254
  • [40] Detection of Minimal Residual Disease (MRD) in High Risk Neuroblastoma Correlates with Outcome: Final Results of International GPOH-DCOG Prospective Validation Study
    Van Zogchel, L.
    De Carolis, B.
    van Wezel, E.
    Stutterheim, J.
    Zappeij-Kannegieter, L.
    van Doornum, M.
    Schumacher-Kuckelkorn, R.
    Gecht, J.
    Simon, T.
    Caron, H.
    Fiocco, M.
    van der Schoot, E.
    Hero, B.
    Berthold, F.
    Tytgat, G.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S38 - S38
12345